Serum relaxin concentrations in women following the administration of 16,16-dimethyl-trans-delta 2-PGE1 methyl ester during early pregnancy.
Serum relaxin was estimated in 11 women during termination of first-trimester pregnancy with 16,16-dimethyl-trans-delta 2-PGE1 methyl ester (16 DM-PGE1). Vaginal administration of 16 DM-PGE1 was associated with a significant increase in serum relaxin.
D000032:Abortion, Therapeutic; D000527:Alprostadil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007700:Kinetics; D008600:Menstruation-Inducing Agents / Q000627:therapeutic use*; D011247:Pregnancy / Q000097:blood*; D011261:Pregnancy Trimester, First; D011374:Progesterone / Q000097:blood; D012065:Relaxin / Q000097:blood*
D008600:Menstruation-Inducing Agents; D011374:Progesterone; C037940:16,16-dimethyl-delta2-prostaglandin E1; D012065:Relaxin; D000527:Alprostadil